ClinicalTrials.gg
RecruitingNCT07256145Updated Dec 1, 2025

Comparison Between the Efficacy of Ultrasound-guided Erector Spinae Plane Block and Conventional Treatment for Pain Management in Patients With Post-herpetic Neuralgia

An interventional study of erector spinae plane block in Post-Herpetic Neuralgia, sponsored by Alexandria University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Aug 2025, registered Nov 2025).
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Neuralgia, Postherpetic with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Neuralgia, Postherpetic · Egypt.

Planned enrollment
5th of 10
60 · median 56
Started
2025
with 4 others
No phase
9 of 10
4 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Alexandria University

Among the 10 studies in Neuralgia, Postherpetic with a site in Egypt, this one is the 5th largest by planned enrollment, is one of 5 that started in 2025, is one of 9 with no phase, and was the 8th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

4 of the 10 studies in Neuralgia, Postherpetic with a site in Egypt are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neuralgia, Postherpetic with a site in Egypt, or all of them as a file.
02

Study summary

The present study aims to evaluate the efficacy of ultrasound-guided erector spinae plane block with steroids to relieve pain in cases of post-herpetic neuralgia, patient satisfaction, and record any complications post-injection.

Read the detailed description

The current study will be conducted as a single-blinded prospective randomized controlled study to evaluate the efficacy of ultrasound-guided erector spinae plane block with steroids to relieve pain in cases of post-herpetic neuralgia.

All patients will be evaluated by:

  • Full history taking: including age, sex, presence of co-morbid conditions as well as the presenting complaint.
  • Clinical examination and routine lab investigations that include:

    • Complete blood count (CBC).
    • Fasting blood glucose (FBG).
    • Coagulation profile (bleeding time, prothrombin time, prothrombin activity, international normalized ratio).

Measurements:

Patients will be followed up at 24 hours, 1 week, and 6 weeks after injection.

The following measurements will be recorded:

  1. Pain will be assessed pre- and post-injection using VAS score at 24 hours, 1 week, and 6 weeks post-injection.
  2. Need for analgesic intake post-injection will be assessed at the follow-up periods.
  3. Patient satisfaction using the SAPS score.
  4. Complications post-injection as pain, irritation or infection will be assessed.
03

Conditions studied

  • Post-Herpetic Neuralgia
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with post-herpetic neuralgia not responding to medical treatment.

Exclusion criteria

Exclusion Criteria:

- 1- Patient refusal 2- Age less than 20 years or older than 70 years. 3- Systemic Infection. 4-Patients with dementia or other diseases that could have impaired their memory or cognitive function.

5- patients, severe osteoporosis, and uncontrolled diabetes mellitus.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Injection group

    Procedure: erector spinae plane block

  • No intervention
    conventional group

Interventions

  • Procedureerector spinae plane block

    erector spinae plane block with steroids

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of ultrasound-guided erector spinae plane block with steroids to relieve pain in cases of post-herpetic neuralgia

    by VAS score

    Time frame: 6 weeks

Secondary outcomes

  1. Patient satisfaction

    SAPS score

    Time frame: 6 weeks

  2. Complications

    As pain, irritation or infection

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2026, 6 months after the start.

Of 30 non-industry interventional studies with no phase under Neuralgia, Postherpetic, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 6 months is below that.

Counting every sponsor, half of 32 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 1, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Feb 1, 2026
CompletionEst.
Mar 1, 2026
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07256145
Responsible party
Sponsor
First posted
Dec 1, 2025
Start date
Aug 1, 2025
Primary completion
Feb 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Dec 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion